argenx (ARGX) Competitors $623.82 -2.21 (-0.35%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARGX vs. AMGN, GILD, BNTX, BIIB, MRNA, NBIX, TECH, PCVX, QGEN, and EXELShould you be buying argenx stock or one of its competitors? The main competitors of argenx include Amgen (AMGN), Gilead Sciences (GILD), BioNTech (BNTX), Biogen (BIIB), Moderna (MRNA), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Qiagen (QGEN), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry. argenx vs. Amgen Gilead Sciences BioNTech Biogen Moderna Neurocrine Biosciences Bio-Techne Vaxcyte Qiagen Exelixis Amgen (NASDAQ:AMGN) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, AMGN or ARGX? Amgen has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Does the MarketBeat Community prefer AMGN or ARGX? Amgen received 903 more outperform votes than argenx when rated by MarketBeat users. Likewise, 72.11% of users gave Amgen an outperform vote while only 67.12% of users gave argenx an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes154672.11% Underperform Votes59827.89% argenxOutperform Votes64367.12% Underperform Votes31532.88% Do insiders and institutionals hold more shares of AMGN or ARGX? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, AMGN or ARGX? Amgen has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$32.53B4.35$6.72B$7.8133.72argenx$1.86B20.26-$295.05M-$0.88-708.89 Is AMGN or ARGX more profitable? Amgen has a net margin of 13.00% compared to argenx's net margin of -2.11%. Amgen's return on equity of 168.35% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Amgen13.00% 168.35% 11.18% argenx -2.11%-1.45%-1.29% Do analysts rate AMGN or ARGX? Amgen presently has a consensus price target of $319.67, suggesting a potential upside of 21.37%. argenx has a consensus price target of $639.78, suggesting a potential upside of 2.56%. Given Amgen's higher probable upside, research analysts plainly believe Amgen is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.40argenx 0 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the media prefer AMGN or ARGX? In the previous week, Amgen had 1 more articles in the media than argenx. MarketBeat recorded 14 mentions for Amgen and 13 mentions for argenx. argenx's average media sentiment score of 0.98 beat Amgen's score of 0.28 indicating that argenx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral argenx 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmgen beats argenx on 12 of the 18 factors compared between the two stocks. Ad ProsperityPubIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.66B$2.94B$5.15B$9.08BDividend YieldN/A1.90%5.12%4.26%P/E Ratio-708.8946.7386.9717.20Price / Sales20.26415.061,137.34117.12Price / CashN/A182.1043.2337.85Price / Book9.013.894.794.78Net Income-$295.05M-$42.21M$120.55M$225.60M7 Day Performance-1.39%-2.36%-1.46%-1.36%1 Month Performance2.95%1.83%13.76%0.20%1 Year Performance67.29%16.78%28.67%15.30% argenx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenx3.0083 of 5 stars$623.82-0.4%$639.78+2.6%+67.3%$37.66B$1.86B-708.891,148AMGNAmgen4.4595 of 5 stars$269.63-0.4%$319.68+18.6%-7.3%$144.94B$32.53B34.8626,700Gap UpGILDGilead Sciences4.4294 of 5 stars$92.75+1.0%$96.43+4.0%+16.2%$115.59B$27.12B1,020.6718,000BNTXBioNTech2.0337 of 5 stars$115.76-3.8%$140.76+21.6%+7.4%$27.52B$3.04B-56.016,133BIIBBiogen4.6265 of 5 stars$151.25+0.8%$245.32+62.2%-43.2%$22.04B$9.61B13.697,570Analyst DowngradeMRNAModerna4.2694 of 5 stars$41.63-0.5%$79.50+91.0%-58.5%$16.02B$5.06B-7.195,600NBIXNeurocrine Biosciences4.8337 of 5 stars$134.00+5.8%$165.00+23.1%+5.4%$13.57B$2.24B35.791,400Analyst ForecastTECHBio-Techne4.6302 of 5 stars$76.51+1.1%$82.00+7.2%-5.6%$12.16B$1.17B81.073,100Positive NewsPCVXVaxcyte1.56 of 5 stars$90.74+3.4%$147.50+62.6%+41.7%$11.31BN/A-19.07160Analyst ForecastQGENQiagen3.5165 of 5 stars$45.47+0.2%$51.15+12.5%+0.3%$10.38B$1.97B117.035,967EXELExelixis4.4439 of 5 stars$36.01+2.8%$31.47-12.6%+39.1%$10.28B$2.08B22.461,310Analyst Downgrade Related Companies and Tools Related Companies AMGN Alternatives GILD Alternatives BNTX Alternatives BIIB Alternatives MRNA Alternatives NBIX Alternatives TECH Alternatives PCVX Alternatives QGEN Alternatives EXEL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARGX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
